{"id":506887,"date":"2020-09-14T18:22:01","date_gmt":"2020-09-14T18:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=506887"},"modified":"2020-09-14T18:22:01","modified_gmt":"2020-09-14T18:22:01","slug":"chemotherapyinduced-nausea-and-vomiting-cinv-pipeline-assessment-key-companies-and-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapyinduced-nausea-and-vomiting-cinv-pipeline-assessment-key-companies-and-emerging-drugs_506887.html","title":{"rendered":"Chemotherapy-Induced Nausea and Vomiting (CINV) Pipeline Assessment, Key Companies And Emerging Drugs"},"content":{"rendered":"
\"Chemotherapy-Induced<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Chemotherapy-Induced Nausea and Vomiting (CINV) Pipeline Insight, 2020” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Chemotherapy-Induced Nausea and Vomiting (CINV) market. <\/p>\n<\/div>\n

The Chemotherapy-Induced Nausea and Vomiting (CINV) Pipeline Insight<\/strong><\/span> report embraces in-depth <\/span>commercial assessment and clinical assessment<\/span> of the Chemotherapy-Induced Nausea and Vomiting (CINV) pipeline products from the pre-clinical developmental phase to the marketed phase. <\/span><\/p>\n

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy-Induced Nausea and Vomiting (CINV) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/span><\/p>\n

 <\/span><\/span><\/p>\n

Get FREE sample copy at: <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-nausea-and-vomiting-pipeline-insight<\/a><\/strong><\/p>\n

 \"chemotherapy-induced-nausea-and-vomiting-pipeline-insight\"<\/strong><\/p>\n

The dynamics of Chemotherapy-Induced Nausea and Vomiting (CINV) market<\/strong> is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period of 2020–2030.<\/p>\n

Some of the key players in the Chemotherapy-Induced Nausea and Vomiting (CINV) market includes:<\/strong>
Helsinn Healthcare
Heron Therapeutics
Novartis Therapeutics
Acacia Pharma
And many others.<\/p>\n

 <\/p>\n

Drugs Covered<\/strong>
APD403
Fosnetupitant IV
Fosnetupitant\/palonosetron oral suspension (for pediatric patients)
And many others.<\/p>\n

 <\/p>\n

Chemotherapy-Induced Nausea and Vomiting (CINV) Pipeline Analysis<\/strong><\/a><\/p>\n

The report provides insights into: <\/span><\/p>\n